Professor Robin Jones is Head of the Royal Marsden Hospital Sarcoma Unit and leader of the Sarcoma Clinical Trials Team at the Institute of Cancer Research (ICR). He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas and has himself led several important international clinical trials in LMS. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.

Professor Huang, who trained at Imperial College and in Biological Engineering at MIT (Massachusetts Institute of Technology), is the Deputy Director of the Joint Royal Marsden-ICR Sarcoma Research Centre, one of the largest sarcoma research centres in Europe. He is leader of the Molecular and Systems Oncology Group at the ICR. Professor Huang also serves as Vice Chair of the Pathology & Translational Research Committee of the EORTC Soft Tissue and Bone Sarcoma Group and as a member of several panels including the NCRI Sarcoma Clinical Studies Group.

Dr. Charles Akle FRCS trained at Guy’s Hospital in London, where he was awarded the prestigious Hallett Prize, and researched into transplantation and immunology early in his career. He was a prominent London-based surgeon and a pioneer in the development of laparoscopic surgery. After retiring from clinical practice in 2007, he founded a biopharmaceutical company developing novel immunotherapeutic products. His clinical experience in oncology and the relationship with immunity has laid the foundations for his current interests and specifically in chronic inflammation and its link to cancer, stress and the microbiome. Dr. Akle consults actively in immunotherapy in the biotechnology arena. He is a Global Ambassador for the University of Boulder, Colorado, and is involved in immunological research projects there and elsewhere.

Professor Bahr is Provost of the University of Balamand in Lebanon, where he was until recently Professor of Immunology and Virology. He trained at the American University of Beirut and Middlesex Hospital School, University of London. He has spent much of his career in the development of the use of immunotherapy in the management of chronic infections and tumours. He was previously head of the HIV Department at the Pasteur Institute in Lille, France. He remains actively involved in research: recent work includes the clinical evaluation of a new generation of immunotherapeutics, the molecular analysis of the mechanism of action of synthetic immunomodulators and the identification of novel cellular genes mediating innate immunity.

Dr Gaya is a consultant clinical oncologist specialising in gastrointestinal tumours using chemotherapy, radiotherapy, immunotherapy, biological therapies, and data from tumour genome analysis. His main interests are in the areas of functional cancer imaging. Dr Gaya qualified at St George’s Hospital Medical School (University of London). He trained in clinical oncology at Imperial College and St Bartholomew’s Hospital and subsequently undertook a Cancer Research UK MD Fellowship at University College London.

Satvinder Mudan is a specialist in surgical oncology, npw consulting at The London Clinic after more than 20 years as an NHS consultant, including at St George’s Hospital and The Royal Marsden Hospital, where he was Medical Director for Private Care. After qualification from St Bartholomew’s Hospital Medical School, his training included fellowships in surgical oncology at Memorial Sloan-Kettering in New York and at the National Cancer Centre in Tokyo. He has a strong research and clinical interest in sarcoma, and is a member of the EORTC working group in GI cancers and soft tissue sarcoma.

Dr Sivakumar is Associate Professor of Oncology and a research active oncologist at the Institute of Immunology and Immunotherapy at the University of Birmingham where he also runs an active clinical trials programme. He has a specialist interest in improving the survival of patients with pancreatic cancer through finding opportunities to diagnose the disease earlier and informing new targets by studying the biology of the disease. He was previously clinical career development fellow at the University of Oxford and BMS Translation fellow. He qualified at Queen Mary’s, University of London and has a PhD in Biochemistry from the University of Cambridge.